Pharma

Rentosertib Shows Potential to Lower Biological Age in Small AI Drug Study

01

Rentosertib, an AI-developed drug, lowered biological age markers in patients with idiopathic pulmonary fibrosis.

02

Study analyzed blood samples from 42 patients, showing consistent results across six aging clocks.

03

Findings are preliminary, emphasizing the need for further research into the drug's effects on aging.

04

Rentosertib targets a specific disease mechanism identified by generative AI, showcasing AI's potential in drug development.

05

The research highlights a shift towards clinical testing for AI-discovered drug candidates in modern medicine.